Patient characteristics at baseline and at relapse
| Factor . | Overall . | Paired samples . | ||||
|---|---|---|---|---|---|---|
| Baseline, n/N (%) . | Relapse, n/N (%) . | P . | Baseline, n/N (%) . | Relapse, n/N (%) . | P . | |
| Age ≥ 65 y | 25/120 (21) | 39/120 (33) | .041 | 13/71 (18) | 23/71 (32) | .054 |
| Albumin < 3.5 g/dL | 28/120 (23) | 9/115 (8) | .001 | 14/71 (20) | 6/70 (9) | .058 |
| B2M ≥ 3.5 mg/L | 55/120 (46) | 41/103 (40) | .365 | 35/71 (49) | 25/63 (40) | .264 |
| B2M ≥ 5.5 mg/L | 23/120 (19) | 16/103 (16) | .476 | 15/71 (21) | 11/63 (17) | .592 |
| CRP ≥ 8 mg/L | 45/117 (38) | 6/105 (6) | < .001 | 20/69 (29) | 4/63 (6) | < .001 |
| LDH ≥ 190 U/L | 36/120 (30) | 37/108 (34) | .491 | 20/71 (28) | 18/63 (29) | .959 |
| Hb < 10 g/dL | 41/120 (34) | 21/112 (19) | .008 | 27/71 (38) | 12/67 (18) | .009 |
| Platelets < 150 × 109/μL | 30/120 (25) | 64/112 (57) | < .001 | 18/71 (25) | 39/67 (58) | < .001 |
| Cytogenetic abnormalities | 50/118 (42) | 72/106 (68) | < .001 | 36/70 (51) | 51/68 (75) | .004 |
| GEP high-risk | 15/71 (21) | 46/120 (38) | .014 | 15/71 (21) | 28/71 (39) | .018 |
| GEP CD-1 | 5/71 (7) | 5/104 (5) | .532* | 5/71 (7) | 5/67 (7) | .924 |
| GEP CD-2 | 4/71 (6) | 6/104 (6) | .970* | 4/71 (6) | 3/67 (4) | .757* |
| GEP HY | 21/71 (30) | 21/104 (20) | .153 | 21/71 (30) | 17/67 (25) | .581 |
| GEP LB | 3/71 (4) | 0/104 (0) | .034* | 3/71 (4) | 0/67 (0) | .089* |
| GEP MF | 3/71 (4) | 5/104 (5) | .856* | 3/71 (4) | 3/67 (4) | .942* |
| GEP MS | 17/71 (24) | 26/104 (25) | .873 | 17/71 (24) | 17/67 (25) | .846 |
| GEP MY | 9/71 (13) | 9/104 (9) | .390 | 9/71 (13) | 5/67 (7) | .311 |
| GEP PR | 9/71 (13) | 32/104 (31) | .006 | 9/71 (13) | 17/67 (25) | .057 |
| TP53 deletion (Affymetrix expression < 727) | 6/71 (8) | 24/106 (23) | .014 | 6/71 (8) | 13/68 (19) | .067 |
| Factor . | Overall . | Paired samples . | ||||
|---|---|---|---|---|---|---|
| Baseline, n/N (%) . | Relapse, n/N (%) . | P . | Baseline, n/N (%) . | Relapse, n/N (%) . | P . | |
| Age ≥ 65 y | 25/120 (21) | 39/120 (33) | .041 | 13/71 (18) | 23/71 (32) | .054 |
| Albumin < 3.5 g/dL | 28/120 (23) | 9/115 (8) | .001 | 14/71 (20) | 6/70 (9) | .058 |
| B2M ≥ 3.5 mg/L | 55/120 (46) | 41/103 (40) | .365 | 35/71 (49) | 25/63 (40) | .264 |
| B2M ≥ 5.5 mg/L | 23/120 (19) | 16/103 (16) | .476 | 15/71 (21) | 11/63 (17) | .592 |
| CRP ≥ 8 mg/L | 45/117 (38) | 6/105 (6) | < .001 | 20/69 (29) | 4/63 (6) | < .001 |
| LDH ≥ 190 U/L | 36/120 (30) | 37/108 (34) | .491 | 20/71 (28) | 18/63 (29) | .959 |
| Hb < 10 g/dL | 41/120 (34) | 21/112 (19) | .008 | 27/71 (38) | 12/67 (18) | .009 |
| Platelets < 150 × 109/μL | 30/120 (25) | 64/112 (57) | < .001 | 18/71 (25) | 39/67 (58) | < .001 |
| Cytogenetic abnormalities | 50/118 (42) | 72/106 (68) | < .001 | 36/70 (51) | 51/68 (75) | .004 |
| GEP high-risk | 15/71 (21) | 46/120 (38) | .014 | 15/71 (21) | 28/71 (39) | .018 |
| GEP CD-1 | 5/71 (7) | 5/104 (5) | .532* | 5/71 (7) | 5/67 (7) | .924 |
| GEP CD-2 | 4/71 (6) | 6/104 (6) | .970* | 4/71 (6) | 3/67 (4) | .757* |
| GEP HY | 21/71 (30) | 21/104 (20) | .153 | 21/71 (30) | 17/67 (25) | .581 |
| GEP LB | 3/71 (4) | 0/104 (0) | .034* | 3/71 (4) | 0/67 (0) | .089* |
| GEP MF | 3/71 (4) | 5/104 (5) | .856* | 3/71 (4) | 3/67 (4) | .942* |
| GEP MS | 17/71 (24) | 26/104 (25) | .873 | 17/71 (24) | 17/67 (25) | .846 |
| GEP MY | 9/71 (13) | 9/104 (9) | .390 | 9/71 (13) | 5/67 (7) | .311 |
| GEP PR | 9/71 (13) | 32/104 (31) | .006 | 9/71 (13) | 17/67 (25) | .057 |
| TP53 deletion (Affymetrix expression < 727) | 6/71 (8) | 24/106 (23) | .014 | 6/71 (8) | 13/68 (19) | .067 |
n indicates number with factor; N, number with valid data for factor; B2M, β2-microglobulin; CRP, C-reactive protein; and LDH, lactic dehydrogenase.
Sample size assumption for χ2 test is suspect.